Health News

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.

Read more

Filed under: Pharmacy News
Tags: gene, Genetic, medicine, Oncology, Pharmacy, Protein, Tumor

Related posts

• Scientists Rediscover Gene Target For Cancer Therapy (0)
  Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies... Read [...]
  
  
• Epeius Biotechnologies’ REXIN-G, A Tumor-Targeted Genetic Medicine For Metastatic Cancer, Gains Phase 3 Product Designation From The U.S. FDA (0)
  Epeius Biotechnologies announced that the U.S. FDA has granted Phase 3 status for the Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek out and destroy metastatic cancer. According to Dr... Read more [tags] Pharmacy News [/tags]
  
  
• Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers (0)
  A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology. Read [...]
  
  
• To Reach, Perchance To Kill The Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That ‘Sea Of Troubles’ (0)
  Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S... Read more [tags] Pharmacy News [/tags]
  
  
• Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer (0)
  Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target. Read more [tags] Pharmacy News [/tags]